InVivo Therapeutics Holdings Corp. (NVIV),
a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and other neurotrauma conditions, today congratulates InVivo Therapeutics’ sponsored athlete Jason Fowler on winning the 2012 Ironman 70.3 World Triathlon Championships in Las Vegas, NV.
Jason Fowler (Photo: Business Wire)
As a nationally ranked amateur motocross racer, Fowler was paralyzed from the chest down at the age of 17 as the result of a motorcycle accident. Following his accident Fowler remained an avid athlete, and has since completed 150 road races, 30 marathons, and 29 triathlons, and has won several local and national competitions including two World Championships. He also regularly volunteers his time to traumatically injured children and trains aspiring athletes.
Most recently, Fowler took first place in the 2012 Ironman 70.3 World Triathlon Championships in Las Vegas, NV. As a triathlete, Fowler competes conventionally in the swim and participates in the bike ride stage using a handcycle, and in the run portion using a racing wheelchair. Remarkably, the entire distance of the race is covered using only the strength and endurance of the upper body.
“Jason’s commitment to his sport is only exceeded by his commitment to the spinal cord injury community,” said Frank Reynolds, InVivo Chief Executive Officer. “We all know the importance of first responders at any emergency, but well after the doctors, nurses, and rehabilitation experts finish their work, Jason and his team at the Boston Chapter of the National Spinal Cord Injury Association arrive to teach patients how to adjust and adapt to a new set of possibilities for their lives. Jason is a Ironnman in every sense of the word.”
To read more and see a great video about Jason, please visit:
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is utilizing polymers as a platform technology to develop treatments to improve function in individuals paralyzed from traumatic spinal cord injuries. The company was founded in 2005 based on proprietary technology co-invented by Robert S. Langer, ScD. Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who is affiliated with Massachusetts General Hospital. In 2011, the company earned the prestigious 2011 David F. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. The publicly traded company is headquartered in Cambridge, MA. For more details, visit
Safe Harbor Statement
Certain statements contained in this press release that are not historical facts may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934, and the Company intends that such statements are subject to the safe harbor created thereby. These statements include, but are not limited to, those relating to the expected approval of the FDA to conduct human clinical trials for the Company’s products, the expected commencement date of any approved human clinical trials, the expected size of the pilot study, the expectation that the scaffold product will be regulated under a HDE pathway, and the expected acceleration of commercialization of the Company’s products resulting therefrom. These forward-looking statements are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to obtain FDA approval to conduct human clinical trials; whether the human clinical trials produce acceptable results; the Company’s ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company’s products and technology in connection with spinal cord injuries; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our Annual Report on Form 10-K for the year ended December 31, 2011 and subsequent filings with the SEC.